Autolus Therapeutics plc
corporate_fare Company Profile
Autolus Therapeutics plc (NASDAQ:AUTL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for AUTL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for AUTL spans 10-Q, 8-K, S-3, 10-K.
Recent high-impact activity:
- Autolus' Obe-cel Wins FDA RMAT Designation for Lupus, Accelerating Path to Market
- Autolus Therapeutics Removes Going Concern Doubt, Reports Strong Q2 Revenue Growth & Operational Efficiency
- Autolus Q2 Revenue Surges 119% to $45.7M; 2026 Guidance Raised to $140–$150M
- Autolus Q2 Revenue Hits ~$45M, Raises FY Guidance to $150M, Secures $250M Credit Line
- Autolus lifts 2026 guidance to $140–$150M, lands $75M credit facility, and pushes cash runway into 2028
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for AUTL, detected from its recent SEC filings · based on capital-structure filings through 2026-04-10.
Establishes $150 Million Shelf Registration · Signals Future Capital Raises
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →